Success Metrics

Clinical Success Rate
89.5%

Based on 17 completed trials

Completion Rate
89%(17/19)
Active Trials
1(5%)
Results Posted
112%(19 trials)
Terminated
2(10%)

Phase Distribution

Ph phase_2
7
35%
Ph phase_3
2
10%
Ph phase_1
10
50%
Ph early_phase_1
1
5%

Phase Distribution

11

Early Stage

7

Mid Stage

2

Late Stage

Phase Distribution20 total trials
Early Phase 1First-in-human
1(5.0%)
Phase 1Safety & dosage
10(50.0%)
Phase 2Efficacy & side effects
7(35.0%)
Phase 3Large-scale testing
2(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

89.5%

17 of 19 finished

Non-Completion Rate

10.5%

2 ended early

Currently Active

1

trials recruiting

Total Trials

20

all time

Status Distribution
Active(1)
Completed(17)
Terminated(2)

Detailed Status

Completed17
Terminated2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
20
Active
1
Success Rate
89.5%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (5.0%)
Phase 110 (50.0%)
Phase 27 (35.0%)
Phase 32 (10.0%)

Trials by Status

recruiting15%
terminated210%
completed1785%

Recent Activity

1 active trials
Showing 5 of 20
recruitingphase_1

A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

NCT06297590
completedphase_1

18F-AV-1451 High Resolution Autopsy Study

NCT02350634
completedphase_1

A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease

NCT03019536
completedphase_1

Flortaucipir PET Imaging in Subjects With FTD

NCT03040713
terminatedphase_1

Flortaucipir 18F PET Imaging in BIOCARD Study

NCT03052972
View all 20 trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT06297590Phase 1

A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
NCT02350634Phase 1

18F-AV-1451 High Resolution Autopsy Study

Completed
NCT03019536Phase 1

A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease

Completed
NCT03040713Phase 1

Flortaucipir PET Imaging in Subjects With FTD

Completed
NCT03052972Phase 1

Flortaucipir 18F PET Imaging in BIOCARD Study

Terminated
NCT04468347Phase 1

Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease

Completed
NCT04474405Early Phase 1

Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects

Completed
NCT02016560Phase 2

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects

Completed
NCT02278354Phase 1

Tau Imaging in Professional Fighters

Completed
NCT02278367Phase 2

Clinical Evaluation of Flortaucipir F 18

Completed
NCT02051764Phase 2

Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

Terminated
NCT02079766Phase 2

18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy

Completed
NCT01992380Phase 1

A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects

Completed
NCT02516046Phase 3

18F-AV-1451 Autopsy Study

Completed
NCT03901105Phase 3

Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease

Completed
NCT02167594Phase 1

Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers

Completed
NCT03467477Phase 2

Tau Screening Study in Subjects With Early Symptomatic AD

Completed
NCT03322462Phase 2

Tau Screening Study in Patients With Early Symptomatic AD

Completed
NCT02795780Phase 2

Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05

Completed
NCT02336360Phase 1

Augmenting Flortaucipir Dosimetry Estimates

Completed

All 20 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
20